Deutsch English Français

Contact

EP2713727

European procedure

Quick help

Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...

News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...

Extract from the Register of European Patents

EP About this file: EP2713727

EP2713727 - COMBINATION OF MEK INHIBITORS AND SELECTIVE INHIBITORS OF AURORA A KINASE [Right-click to bookmark this link]
Status	No opposition filed within time limit Status updated on 04.02.2022 Database last updated on 14.09.2024
Former	The patent has been granted Status updated on 26.02.2021
Former	Grant of patent is intended Status updated on 13.10.2020
Former	Examination is in progress Status updated on 15.07.2020
Former	Grant of patent is intended Status updated on 05.03.2020
Former	Examination is in progress Status updated on 23.11.2018
Most recent event Tooltip	06.09.2024	Lapse of the patent in a contracting state New state(s): MT	published on 09.10.2024 [2024/41]
Applicant(s)	For all designated states Millennium Pharmaceuticals, Inc. 40 Landsdowne Street Cambridge, MA 02139 / US
	For all designated states Takeda Pharmaceutical Company Ltd. Oncology DDU C-1 2F 1110 26-1 Muraokahigashi 2-chome Fujisawa Kanagawa 251-0012 / JP
	[2014/15]
Inventor(s)	01 / CHAKRAVARTY, Arijit 2 Hawthorne Road Lexington, MA 02420 / US
	02 / VINCENT, Patrick C/o Takeda California, Inc. 10410 Science Center Drive San Diego, CA 92121 / US
	[2021/13]
Former [2014/15]	01 / CHAKRAVARTY, Arijit 2 Hawthorne Road Lexington, MA 02420 / US
	02 / VINCENT, Patrick C/o Takeda California Inc. 10410 Science Center Drive San Diego, CA 92121 / US
Representative(s)	Harris, Jennifer Lucy, et al Kilburn & Strode LLP Lacon London 84 Theobalds Road London WC1X 8NL / GB
	[2021/13]
Former [2014/15]	Harris, Jennifer Lucy, et al Kilburn & Strode LLP 20 Red Lion Street London WC1R 4PJ / GB
Application number, filing date	12793812.4	04.06.2012
	[2021/13]
	WO2012US40733
Priority number, date	US201161493217P	03.06.2011 Original published format: US 201161493217 P
	US201261613207P	20.03.2012 Original published format: US 201261613207 P
	[2014/15]
Filing language	EN
Procedural language	EN
Publication	Type:	A1 Application with search report
	No.:	WO2012167247
	Date:	06.12.2012
	Language:	EN
	[2012/49]
	Type:	A1 Application with search report
	No.:	EP2713727
	Date:	09.04.2014
	Language:	EN
	The application published by WIPO in one of the EPO official languages on 06.12.2012 takes the place of the publication of the European patent application.
	[2014/15]
	Type:	B1 Patent specification
	No.:	EP2713727
	Date:	31.03.2021
	Language:	EN
	[2021/13]
Search report(s)	International search report - published on:	US	06.12.2012
	(Supplementary) European search report - dispatched on:	EP	24.09.2014
Classification	IPC:	A61K45/06, A61K31/519, A61K31/55, A61P35/00	[2014/43]
	CPC:	A61K31/55 (EP,US); A61K31/519 (EP,US); A61K45/06 (EP,US); A61P35/00 (EP); A61P43/00 (EP)
	C-Set:	A61K31/519, A61K2300/00 (EP,US); A61K31/55, A61K2300/00 (US,EP)
	Former IPC [2014/15]	A01N43/00
Designated contracting states	AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2014/15]
Extension states	BA	02.01.2014
	ME	02.01.2014
Title	German:	KOMBINATION AUS MEK-HEMMERN UND SELEKTIVEN HEMMERN DER AURORA-A-KINASE	[2014/15]
	English:	COMBINATION OF MEK INHIBITORS AND SELECTIVE INHIBITORS OF AURORA A KINASE	[2014/15]
	French:	COMBINAISON D'INHIBITEURS DE MEK ET D'INHIBITEURS SÉLECTIFS DE KINASE AURORA A	[2014/15]
Entry into regional phase	02.01.2014	National basic fee paid
	02.01.2014	Search fee paid
	02.01.2014	Designation fee(s) paid
	02.01.2014	Examination fee paid
Examination procedure	02.01.2014	Examination requested [2014/15]
	14.04.2015	Amendment by applicant (claims and/or description)
	23.11.2018	Despatch of a communication from the examining division (Time limit: M04)
	26.03.2019	Reply to a communication from the examining division
	25.07.2019	Despatch of a communication from the examining division (Time limit: M06)
	30.01.2020	Reply to a communication from the examining division
	06.03.2020	Communication of intention to grant the patent
	13.07.2020	Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
	14.10.2020	Communication of intention to grant the patent
	19.02.2021	Fee for grant paid
	19.02.2021	Fee for publishing/printing paid
	19.02.2021	Receipt of the translation of the claim(s)
Divisional application(s)	The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is 23.11.2018
Opposition(s)	04.01.2022	No opposition filed within time limit [2022/10]
Fees paid	Renewal fee
	30.06.2014	Renewal fee patent year 03
	29.06.2015	Renewal fee patent year 04
	27.06.2016	Renewal fee patent year 05
	27.06.2017	Renewal fee patent year 06
	27.06.2018	Renewal fee patent year 07
	27.06.2019	Renewal fee patent year 08
	29.06.2020	Renewal fee patent year 09
Opt-out from the exclusive Tooltip competence of the Unified Patent Court	See the Register of the Unified Patent Court for opt-out data
	Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition Tooltip	HU	04.06.2012
	AL	31.03.2021
	AT	31.03.2021
	CY	31.03.2021
	CZ	31.03.2021
	DK	31.03.2021
	EE	31.03.2021
	ES	31.03.2021
	FI	31.03.2021
	GR	31.03.2021
	HR	31.03.2021
	IT	31.03.2021
	LT	31.03.2021
	LV	31.03.2021
	MC	31.03.2021
	MK	31.03.2021
	MT	31.03.2021
	NL	31.03.2021
	PL	31.03.2021
	RO	31.03.2021
	RS	31.03.2021
	SE	31.03.2021
	SI	31.03.2021
	SK	31.03.2021
	SM	31.03.2021
	IE	04.06.2021
	LU	04.06.2021
	BE	30.06.2021
	BG	30.06.2021
	CH	30.06.2021
	LI	30.06.2021
	NO	30.06.2021
	IS	31.07.2021
	PT	02.08.2021
	[2024/41]
Former [2024/22]	HU	04.06.2012
	AL	31.03.2021
	AT	31.03.2021
	CY	31.03.2021
	CZ	31.03.2021
	DK	31.03.2021
	EE	31.03.2021
	ES	31.03.2021
	FI	31.03.2021
	GR	31.03.2021
	HR	31.03.2021
	IT	31.03.2021
	LT	31.03.2021
	LV	31.03.2021
	MC	31.03.2021
	MK	31.03.2021
	NL	31.03.2021
	PL	31.03.2021
	RO	31.03.2021
	RS	31.03.2021
	SE	31.03.2021
	SI	31.03.2021
	SK	31.03.2021
	SM	31.03.2021
	IE	04.06.2021
	LU	04.06.2021
	BE	30.06.2021
	BG	30.06.2021
	CH	30.06.2021
	LI	30.06.2021
	NO	30.06.2021
	IS	31.07.2021
	PT	02.08.2021
Former [2023/36]	HU	04.06.2012
	AL	31.03.2021
	AT	31.03.2021
	CY	31.03.2021
	CZ	31.03.2021
	DK	31.03.2021
	EE	31.03.2021
	ES	31.03.2021
	FI	31.03.2021
	GR	31.03.2021
	HR	31.03.2021
	IT	31.03.2021
	LT	31.03.2021
	LV	31.03.2021
	MC	31.03.2021
	NL	31.03.2021
	PL	31.03.2021
	RO	31.03.2021
	RS	31.03.2021
	SE	31.03.2021
	SI	31.03.2021
	SK	31.03.2021
	SM	31.03.2021
	IE	04.06.2021
	LU	04.06.2021
	BE	30.06.2021
	BG	30.06.2021
	CH	30.06.2021
	LI	30.06.2021
	NO	30.06.2021
	IS	31.07.2021
	PT	02.08.2021
Former [2023/28]	HU	04.06.2012
	AL	31.03.2021
	AT	31.03.2021
	CY	31.03.2021
	CZ	31.03.2021
	DK	31.03.2021
	EE	31.03.2021
	ES	31.03.2021
	FI	31.03.2021
	HR	31.03.2021
	IT	31.03.2021
	LT	31.03.2021
	LV	31.03.2021
	MC	31.03.2021
	NL	31.03.2021
	PL	31.03.2021
	RO	31.03.2021
	RS	31.03.2021
	SE	31.03.2021
	SI	31.03.2021
	SK	31.03.2021
	SM	31.03.2021
	IE	04.06.2021
	LU	04.06.2021
	BE	30.06.2021
	BG	30.06.2021
	CH	30.06.2021
	LI	30.06.2021
	NO	30.06.2021
	IS	31.07.2021
	PT	02.08.2021
Former [2023/24]	AL	31.03.2021
	AT	31.03.2021
	CY	31.03.2021
	CZ	31.03.2021
	DK	31.03.2021
	EE	31.03.2021
	ES	31.03.2021
	FI	31.03.2021
	HR	31.03.2021
	IT	31.03.2021
	LT	31.03.2021
	LV	31.03.2021
	MC	31.03.2021
	NL	31.03.2021
	PL	31.03.2021
	RO	31.03.2021
	RS	31.03.2021
	SE	31.03.2021
	SI	31.03.2021
	SK	31.03.2021
	SM	31.03.2021
	IE	04.06.2021
	LU	04.06.2021
	BE	30.06.2021
	BG	30.06.2021
	CH	30.06.2021
	LI	30.06.2021
	NO	30.06.2021
	IS	31.07.2021
	PT	02.08.2021
Former [2022/36]	AL	31.03.2021
	AT	31.03.2021
	CZ	31.03.2021
	DK	31.03.2021
	EE	31.03.2021
	ES	31.03.2021
	FI	31.03.2021
	HR	31.03.2021
	IT	31.03.2021
	LT	31.03.2021
	LV	31.03.2021
	MC	31.03.2021
	NL	31.03.2021
	PL	31.03.2021
	RO	31.03.2021
	RS	31.03.2021
	SE	31.03.2021
	SI	31.03.2021
	SK	31.03.2021
	SM	31.03.2021
	IE	04.06.2021
	LU	04.06.2021
	BE	30.06.2021
	BG	30.06.2021
	CH	30.06.2021
	LI	30.06.2021
	NO	30.06.2021
	IS	31.07.2021
	PT	02.08.2021
Former [2022/34]	AL	31.03.2021
	AT	31.03.2021
	CZ	31.03.2021
	DK	31.03.2021
	EE	31.03.2021
	ES	31.03.2021
	FI	31.03.2021
	HR	31.03.2021
	LT	31.03.2021
	LV	31.03.2021
	MC	31.03.2021
	NL	31.03.2021
	PL	31.03.2021
	RO	31.03.2021
	RS	31.03.2021
	SE	31.03.2021
	SI	31.03.2021
	SK	31.03.2021
	SM	31.03.2021
	IE	04.06.2021
	LU	04.06.2021
	BE	30.06.2021
	BG	30.06.2021
	CH	30.06.2021
	LI	30.06.2021
	NO	30.06.2021
	IS	31.07.2021
	PT	02.08.2021
Former [2022/29]	AL	31.03.2021
	AT	31.03.2021
	CZ	31.03.2021
	DK	31.03.2021
	EE	31.03.2021
	ES	31.03.2021
	FI	31.03.2021
	HR	31.03.2021
	LT	31.03.2021
	LV	31.03.2021
	MC	31.03.2021
	NL	31.03.2021
	PL	31.03.2021
	RO	31.03.2021
	RS	31.03.2021
	SE	31.03.2021
	SI	31.03.2021
	SK	31.03.2021
	SM	31.03.2021
	IE	04.06.2021
	LU	04.06.2021
	BG	30.06.2021
	CH	30.06.2021
	LI	30.06.2021
	NO	30.06.2021
	IS	31.07.2021
	PT	02.08.2021
Former [2022/23]	AL	31.03.2021
	AT	31.03.2021
	CZ	31.03.2021
	DK	31.03.2021
	EE	31.03.2021
	ES	31.03.2021
	FI	31.03.2021
	HR	31.03.2021
	LT	31.03.2021
	LV	31.03.2021
	MC	31.03.2021
	NL	31.03.2021
	PL	31.03.2021
	RO	31.03.2021
	RS	31.03.2021
	SE	31.03.2021
	SK	31.03.2021
	SM	31.03.2021
	IE	04.06.2021
	LU	04.06.2021
	BG	30.06.2021
	CH	30.06.2021
	LI	30.06.2021
	NO	30.06.2021
	IS	31.07.2021
	PT	02.08.2021
Former [2022/21]	AL	31.03.2021
	AT	31.03.2021
	CZ	31.03.2021
	DK	31.03.2021
	EE	31.03.2021
	ES	31.03.2021
	FI	31.03.2021
	HR	31.03.2021
	LT	31.03.2021
	LV	31.03.2021
	MC	31.03.2021
	NL	31.03.2021
	PL	31.03.2021
	RO	31.03.2021
	RS	31.03.2021
	SE	31.03.2021
	SK	31.03.2021
	SM	31.03.2021
	IE	04.06.2021
	LU	04.06.2021
	BG	30.06.2021
	CH	30.06.2021
	LI	30.06.2021
	NO	30.06.2021
	PT	02.08.2021
	IS	23.12.2021
Former [2022/18]	AL	31.03.2021
	AT	31.03.2021
	CZ	31.03.2021
	DK	31.03.2021
	EE	31.03.2021
	ES	31.03.2021
	FI	31.03.2021
	HR	31.03.2021
	LT	31.03.2021
	LV	31.03.2021
	MC	31.03.2021
	NL	31.03.2021
	PL	31.03.2021
	RO	31.03.2021
	RS	31.03.2021
	SE	31.03.2021
	SK	31.03.2021
	SM	31.03.2021
	LU	04.06.2021
	BG	30.06.2021
	NO	30.06.2021
	PT	02.08.2021
	IS	23.12.2021
Former [2022/10]	AL	31.03.2021
	AT	31.03.2021
	CZ	31.03.2021
	DK	31.03.2021
	EE	31.03.2021
	ES	31.03.2021
	FI	31.03.2021
	HR	31.03.2021
	LT	31.03.2021
	LV	31.03.2021
	MC	31.03.2021
	NL	31.03.2021
	PL	31.03.2021
	RO	31.03.2021
	RS	31.03.2021
	SE	31.03.2021
	SK	31.03.2021
	SM	31.03.2021
	BG	30.06.2021
	NO	30.06.2021
	PT	02.08.2021
	IS	23.12.2021
Former [2022/08]	AL	31.03.2021
	AT	31.03.2021
	CZ	31.03.2021
	DK	31.03.2021
	EE	31.03.2021
	ES	31.03.2021
	FI	31.03.2021
	HR	31.03.2021
	LT	31.03.2021
	LV	31.03.2021
	MC	31.03.2021
	NL	31.03.2021
	PL	31.03.2021
	RO	31.03.2021
	RS	31.03.2021
	SE	31.03.2021
	SK	31.03.2021
	SM	31.03.2021
	BG	30.06.2021
	NO	30.06.2021
	IS	31.07.2021
	PT	02.08.2021
Former [2022/07]	AL	31.03.2021
	AT	31.03.2021
	CZ	31.03.2021
	EE	31.03.2021
	ES	31.03.2021
	FI	31.03.2021
	HR	31.03.2021
	LT	31.03.2021
	LV	31.03.2021
	MC	31.03.2021
	NL	31.03.2021
	PL	31.03.2021
	RO	31.03.2021
	RS	31.03.2021
	SE	31.03.2021
	SK	31.03.2021
	SM	31.03.2021
	BG	30.06.2021
	NO	30.06.2021
	IS	31.07.2021
	PT	02.08.2021
Former [2021/52]	AT	31.03.2021
	CZ	31.03.2021
	EE	31.03.2021
	ES	31.03.2021
	FI	31.03.2021
	HR	31.03.2021
	LT	31.03.2021
	LV	31.03.2021
	NL	31.03.2021
	PL	31.03.2021
	RO	31.03.2021
	RS	31.03.2021
	SE	31.03.2021
	SK	31.03.2021
	SM	31.03.2021
	BG	30.06.2021
	NO	30.06.2021
	IS	31.07.2021
	PT	02.08.2021
Former [2021/51]	AT	31.03.2021
	CZ	31.03.2021
	EE	31.03.2021
	ES	31.03.2021
	FI	31.03.2021
	HR	31.03.2021
	LT	31.03.2021
	LV	31.03.2021
	NL	31.03.2021
	RO	31.03.2021
	RS	31.03.2021
	SE	31.03.2021
	SK	31.03.2021
	SM	31.03.2021
	BG	30.06.2021
	NO	30.06.2021
	IS	31.07.2021
	PT	02.08.2021
Former [2021/50]	AT	31.03.2021
	CZ	31.03.2021
	EE	31.03.2021
	FI	31.03.2021
	HR	31.03.2021
	LT	31.03.2021
	LV	31.03.2021
	NL	31.03.2021
	RO	31.03.2021
	RS	31.03.2021
	SE	31.03.2021
	SK	31.03.2021
	SM	31.03.2021
	BG	30.06.2021
	NO	30.06.2021
	PT	02.08.2021
Former [2021/48]	AT	31.03.2021
	CZ	31.03.2021
	EE	31.03.2021
	FI	31.03.2021
	HR	31.03.2021
	LT	31.03.2021
	LV	31.03.2021
	NL	31.03.2021
	RS	31.03.2021
	SE	31.03.2021
	SM	31.03.2021
	BG	30.06.2021
	NO	30.06.2021
Former [2021/47]	AT	31.03.2021
	FI	31.03.2021
	HR	31.03.2021
	LT	31.03.2021
	LV	31.03.2021
	NL	31.03.2021
	RS	31.03.2021
	SE	31.03.2021
	SM	31.03.2021
	BG	30.06.2021
	NO	30.06.2021
Former [2021/46]	AT	31.03.2021
	FI	31.03.2021
	HR	31.03.2021
	LT	31.03.2021
	LV	31.03.2021
	RS	31.03.2021
	SE	31.03.2021
	SM	31.03.2021
	BG	30.06.2021
	NO	30.06.2021
Former [2021/38]	FI	31.03.2021
	HR	31.03.2021
	LV	31.03.2021
	RS	31.03.2021
	SE	31.03.2021
	BG	30.06.2021
	NO	30.06.2021
Former [2021/37]	FI	31.03.2021
	HR	31.03.2021
	LV	31.03.2021
	RS	31.03.2021
	BG	30.06.2021
	NO	30.06.2021
Former [2021/36]	FI	31.03.2021
	HR	31.03.2021
	BG	30.06.2021
	NO	30.06.2021
Former [2021/35]	FI	31.03.2021
	HR	31.03.2021
	NO	30.06.2021
Former [2021/33]	FI	31.03.2021
	NO	30.06.2021
Documents cited:	Search	[YD]WO2008063525 (MILLENNIUM PHARM INC [US], et al) [YD] 1-15 * pages 26-27, paragraph 65 * * claim - *;
		[YD]US7572784 (CLAIBORNE CHRISTOPHER F [US], et al) [YD] 1-15 * claim - * * column 295, lines 7-8, 11-12, 38-39 *;
		[X] - CARVAJAL RICHARD D ET AL, "Aurora kinases: new targets for cancer therapy", CLINICAL CANCER RESEARCH, THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, (20061201), vol. 12, no. 23, doi:10.1158/1078-0432.CCR-06-1405, ISSN 1078-0432, pages 6869 - 6875, XP002487803 [X] 1,2,10-12,15 * page 6872; table 2; compound ZM447439 * DOI: http://dx.doi.org/10.1158/1078-0432.CCR-06-1405
		[X] - E DOTAN ET AL, "The ongoing roll-out of Aurora kinase inhibitors in cancer treatment ;", DRUGS OF THE FUTURE, (20101001), vol. 35, no. 10, doi:10.1358/dof.2010.35.10.1529819, ISSN 0377-8282, pages 845 - 858, XP055140135 [X] 1,2,10-12,15 * page 852; table III; compounds ZM-447439 * DOI: http://dx.doi.org/10.1358/dof.2010.035.010.1529819
		[Y] - TSENG YA-SHIH ET AL, "Aurora-A overexpression enhances cell-aggregation of Ha-ras transformants through the MEK/ERK signaling pathway", BMC CANCER, BIOMED CENTRAL, LONDON, GB, (20091212), vol. 9, no. 1, doi:10.1186/1471-2407-9-435, ISSN 1471-2407, page 435, XP021067002 [Y] 1-15 * abstract * DOI: http://dx.doi.org/10.1186/1471-2407-9-435
	International search	[Y]WO2008079814 (TAKEDA PHARMACEUTICAL [JP], et al);
		[X]US2010004247 (MUNDT KIRSTEN ELISABETH [DE], et al);
		[A]US2010227838 (SHAH OMAR JAMEEL [US], et al);
		[E] - PUBCHEM, Database accession no. CID 24771867, URL: NCBI, XP003032516
		[A] - DONG ET AL., "Discovery of TAK-733, a potent and selective MEK allosteric site inhibitor for the treatment of cancer", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, (20110122), vol. 21, pages 1315 - 1319, XP028144471 DOI: http://dx.doi.org/10.1016/j.bmcl.2011.01.071
	by applicant	WO2005111039
		US2008045501
		WO2008021038
		WO2008063525
		WO2008079814
		US2008167292
		US7572784
		US2010004247
		US7718648
		WO2010059503
		WO2010134965
		US2010310651
		WO2011014248
		US2011039826
		US8026246
		US2011245234
		- Curr. Med. Chem., (20070000), vol. 14, pages 969 - 985
		- Embo J, (19980000), vol. 17, pages 3052 - 3065
		- Genetics, (19930000), vol. 135, pages 677 - 691
		- Cell, (19950000), vol. 81, pages 95 - 105
		- JCell Sci, (19980000), vol. 111, pages 557 - 572
		- Mol Cancer Ther, (20070000), vol. 6, pages 1851 - 1857
		- J Cell Biol, (20010000), vol. 152, pages 669 - 682
		- J Cell Biol, (20030000), vol. 161, pages 281 - 294
		- Curr Biol, (20020000), vol. 12, pages 894 - 899
		- Genes Cells, (20050000), vol. 10, pages 127 - 137
		- Mol Biol Cell, (20030000), vol. 14, pages 3325 - 3341
		- Mol Cancer Ther, (20090000), vol. 8, no. 7, pages 2046 - 56
		- Int J Cancer, (20060000), vol. 118, pages 357 - 363
		- J Natl Cancer Inst, (20020000), vol. 94, pages 1320 - 1329
		- Int J Oncol, (20040000), vol. 25, pages 1631 - 1639
		- Cancer Res, (20070000), vol. 67, pages 10436 - 10444
		- Clin Cancer Res, (20040000), vol. 10, pages 2065 - 2071
		- Clin Cancer Res, (20070000), vol. 13, pages 4098 - 4104
		- Int J Cancer, (20010000), vol. 92, pages 370 - 373
		- Br J Cancer, (20010000), vol. 84, pages 824 - 831
		- JNatl Cancer Inst, (20020000), vol. 94, pages 1320 - 1329
		- Cancer Res, (20020000), vol. 62, pages 4115 - 4122
		- Mol Cancer Res, (20090000), vol. 7, pages 678 - 688
		- Oncogene, (20060000), vol. 25, pages 1153 - 7158
		- Cell Res, (20060000), vol. 16, pages 356 - 366
		- Oncogene, (20080000), vol. 27, pages 4305 - 4314
		- Nat Genet, (19980000), vol. 20, pages 189 - 193
		- Nat Rev Mol Cell Biol, (20030000), vol. 4, pages 842 - 854
		- Curr Top Dev Biol, (20000000), vol. 49, pages 331 - 42
		- Nat Rev Mol Cell Biol, (20010000), vol. 2, no. 1, pages 21 - 32
		- J Cell Sci, (20070000), vol. 120, pages 2987 - 2996
		- Trends Cell Biol, (19990000), vol. 9, pages 454 - 459
		- Trends Cell Biol, (20050000), vol. 15, pages 241 - 250
		- The Journal of biological chemistry, (20030000), vol. 278, pages 51786 - 51795
		- Mol Cell Biol, (20070000), vol. 27, no. 12, pages 4513 - 25
		- Cell Cycle, (20080000), vol. 7, no. 17, pages 2691 - 704
		- Cell Cycle, (20090000), vol. 8, no. 6, pages 876 - 88
		- Mol Cancer Res, (20100000), vol. 8, no. 3, pages 373 - 84
		- Mol. Cancer Ther, (20090000), vol. 8, no. 7, pages 2046 - 56
		- Oncogene, (19990000), vol. 18, pages 813 - 822
		- J. Clin. Invest., (19970000), vol. 99, pages 1478 - 1483
		- Cancer Res, (20050000), vol. 65, no. 11, pages 4870 - 80
		- Proc. Natl. Acad. Sci., (20070000), vol. 104, page 4106
		- Chem Biol., (20080000), vol. 15, no. 6, pages 552 - 62
		- BERGE et al., J. Pharm. Sci., (19770000), vol. 66, pages 1 - 19
		- Oncogene, (20070000), vol. 26, pages 4689 - 98
		- Mol Biol Cell, (20060000), vol. 17, pages 5227 - 40
		- Cancer Res., (20080000), vol. 68, pages 5113 - 21
	- Cell Cycle, (20110000), vol. 10, pages 481 - 91

The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.

Legal notice
Terms of use
24.2.25; 34p